{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:57:29Z","timestamp":1781672249525,"version":"3.54.5"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007687","name":"Korean Diabetes Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>In patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and sulfonylurea, evidence directly comparing glucagon-like peptide-1 receptor agonists and sodium\u2013glucose cotransporter 2 inhibitors as add-on therapy is limited; therefore, we compared dulaglutide and empagliflozin in this setting. This 12-week, single-center, randomized, open-label, parallel-group pilot study included a 24-week observational extension. Patients with HbA1c\u22657.0% receiving stable doses of metformin and glimepiride were randomized to dulaglutide 0.75 mg\/week or empagliflozin 10 mg\/day. Doses were uptitrated at week 4 if tolerated and maintained for 12 weeks, with follow-up until week 36. The primary endpoint was the change in HbA1c at week 12. Secondary endpoints included changes in glycemic and obesity-related parameters. Exploratory analyses were performed to assess plasma metabolite profiles using liquid chromatography-mass spectrometry, and gut microbiota using 16S rRNA gene sequencing. Twenty-four patients completed the 12-week study (dulaglutide, n=13; empagliflozin, n=11). Both treatments significantly reduced HbA1c at week 12, with no significant between-group difference. Empagliflozin significantly reduced HOMA-IR, whereas dulaglutide significantly increased HOMA-\u03b2. At week 12, empagliflozin was associated with greater reductions in body weight and body fat compared with dulaglutide, whereas these differences were attenuated at week 36. Exploratory analyses suggested potential, modest treatment-related differences in plasma metabolite profiles and microbiome\u2013metabolic associations, without marked alterations in overall microbial diversity. As add-on therapy to metformin and sulfonylurea, both dulaglutide and empagliflozin improved glycemic control, with no significant between-group difference observed in this exploratory pilot study. Empagliflozin induced earlier weight loss, whereas dulaglutide showed more gradual weight reduction over time, accompanied by exploratory findings suggesting possible differences in plasma and microbiome-related metabolic signatures.<\/jats:p>","DOI":"10.3389\/fendo.2026.1843595","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:46:53Z","timestamp":1781671613000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Dulaglutide versus empagliflozin as add-on therapy to metformin and sulfonylurea in type 2 diabetes: a randomized pilot study with exploratory metabolomic and microbiome analyses"],"prefix":"10.3389","volume":"17","author":[{"given":"Ji Eun","family":"Jun","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Medicine, Kyung Hee University School of Medicine, Kyung Hee University Hospital at Gangdong","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da-Hee","family":"Oh","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Medicine, Kyung Hee University School of Medicine, Kyung Hee University Hospital at Gangdong","place":["Seoul, Republic of Korea"]},{"name":"Department of Biomedical Science and Technology, Graduate School, Kyung Hee University","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Kyung","family":"Jeong","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Medicine, Kyung Hee University School of Medicine, Kyung Hee University Hospital at Gangdong","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Jin","family":"Ryu","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Medicine, Kyung Hee University School of Medicine, Kyung Hee University Hospital at Gangdong","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You-Cheol","family":"Hwang","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Medicine, Kyung Hee University School of Medicine, Kyung Hee University Hospital at Gangdong","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu Jeung","family":"Ahn","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Medicine, Kyung Hee University School of Medicine, Kyung Hee University Hospital at Gangdong","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Yeon","family":"Chung","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Medicine, Kyung Hee University School of Medicine, Kyung Hee University Hospital at Gangdong","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwang Pyo","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Applied Chemistry, Institute of Natural Science, Kyung Hee University","place":["Yongin, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2021.0232","article-title":"Clinical efficacy of sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist combination therapy in type 2 diabetes mellitus: Real-world study","volume":"46","author":"Kim","year":"2022","journal-title":"Diabetes Metab J"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1530\/ec-21-0130","article-title":"How glucagon-like peptide 1 receptor agonists work","volume":"10","author":"Andreasen","year":"2021","journal-title":"Endocrine Connections"},{"key":"B3","doi-asserted-by":"publisher","first-page":"19351","DOI":"10.1038\/s41598-019-55524-w","article-title":"Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis","volume":"9","author":"Castellana","year":"2019","journal-title":"Sci Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2023.0282","article-title":"2023 clinical practice guidelines for diabetes mellitus of the Korean Diabetes Association","volume":"47","author":"Choi","year":"2023","journal-title":"Diabetes Metab J"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.55733","article-title":"Risk of dementia among patients with diabetes in a multidisciplinary, primary care management program","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2337\/ds19-0031","article-title":"Combining glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors to target multiple organ defects in type 2 diabetes","volume":"33","author":"Anderson","year":"2020","journal-title":"Diabetes Spectrum: A Publ Am Diabetes Assoc"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012368.pub2","article-title":"Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus","volume":"4","author":"Madsen","year":"2019","journal-title":"Cochrane Database Systematic Rev"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001346","article-title":"DPP4i, thiazolidinediones, or insulin and risks of cancer in patients with type 2 diabetes mellitus on metformin-sulfonylurea dual therapy with inadequate control","volume":"8","author":"Wong","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2019.0043","article-title":"Understanding bile acid signaling in diabetes: From pathophysiology to therapeutic targets","volume":"43","author":"Ferrell","year":"2019","journal-title":"Diabetes Metab J"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2009.08.001","article-title":"TGR5-mediated bile acid sensing controls glucose homeostasis","volume":"10","author":"Thomas","year":"2009","journal-title":"Cell Metab"},{"key":"B11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.tem.2017.11.002","article-title":"Role of bile acids in metabolic control","volume":"29","author":"Molinaro","year":"2018","journal-title":"Trends Endocrinol Metabolism: TEM"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25147784","article-title":"The GLP-1 receptor agonist liraglutide decreases primary bile acids and serotonin in the colon independently of feeding in mice","volume":"25","author":"Nonogaki","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B13","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3390\/jcdd12120471","article-title":"SGLT2 inhibitors confer cardiovascular protection via the gut-kidney-heart axis: Mechanisms and translational perspectives","volume":"12","author":"Tao","year":"2025"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.7570\/jomes.2017.26.3.161","article-title":"Intestinal microbiota contributes to energy balance, metabolic inflammation, and insulin resistance in obesity","volume":"26","author":"Cavallari","year":"2017","journal-title":"J Obes Metab Syndrome"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf351","article-title":"Gut microbiota modulation in GLP-1RA and SGLT-2i therapy: Clinical implications and mechanistic insights in type 2 diabetes","volume":"18","author":"Kanbay","year":"2025","journal-title":"Clin Kidney J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s12913-016-1471-x","article-title":"Clinical and demographic correlates of medication and visit adherence in a large randomized controlled trial","volume":"16","author":"Whittle","year":"2016","journal-title":"BMC Health Serv Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15164","article-title":"Effects of dapagliflozin compared with glimepiride on body composition in Asian patients with type 2 diabetes inadequately controlled with metformin: The BEYOND study","volume":"25","author":"Park","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: Cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-021-01104-z","article-title":"SGLT2 inhibitors and the clinical implications of associated weight loss in type 2 diabetes: A narrative review","volume":"12","author":"Jane\u017e","year":"2021","journal-title":"Diabetes Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-01798-4","article-title":"Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)","volume":"22","author":"Gourdy","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12084","article-title":"Review article: The emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease","volume":"36","author":"Zarrinpar","year":"2012","journal-title":"Alimentary Pharmacol Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2013.06.003","article-title":"Effects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric emptying--preclinical evidence","volume":"28","author":"Werner","year":"2014","journal-title":"J Diabetes Its Complications"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2015.01.001","article-title":"Metabolic effects of intestinal absorption and enterohepatic cycling of bile acids","volume":"5","author":"Ferrebee","year":"2015","journal-title":"Acta Pharm Sin B"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-019-0156-z","article-title":"Gut microbial metabolites in obesity, NAFLD and T2DM","volume":"15","author":"Canfora","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13570","article-title":"Hypoglycaemia and gastric emptying","volume":"21","author":"Marathe","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2174\/1381612824666180912143434","article-title":"Effect of dapagliflozin on intestinal flora in MAFA-deficient mice","volume":"24","author":"Li","year":"2018","journal-title":"Curr Pharm Des"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2009.02.002","article-title":"A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance","volume":"9","author":"Newgard","year":"2009","journal-title":"Cell Metab"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2307","article-title":"Metabolite profiles and the risk of developing diabetes","volume":"17","author":"Wang","year":"2011","journal-title":"Nat Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.958218","article-title":"Gut microbiota: A new target for T2DM prevention and treatment","volume":"13","author":"Liu","year":"2022","journal-title":"Front Endocrinol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.814770","article-title":"Gut microbial signatures for glycemic responses of GLP-1 receptor agonists in type 2 diabetic patients: A pilot study","volume":"12","author":"Tsai","year":"2021","journal-title":"Front Endocrinol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-2257","article-title":"Metformin affects gut microbiome composition and function and circulating short-chain fatty acids: A randomized trial","volume":"44","author":"Mueller","year":"2021","journal-title":"Diabetes Care"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"B35","doi-asserted-by":"publisher","first-page":"94","DOI":"10.14341\/probl13414","article-title":"Summary of the 2023 European society of cardiology clinical guidelines on the management of cardiovascular disease in patients with diabetes mellitus","volume":"70","author":"Erlikh","year":"2024","journal-title":"Probl Endokrinol (Mosk)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1624878","article-title":"Metabolomics uncovers the diabetes metabolic network: From pathophysiological mechanisms to clinical applications","volume":"16","author":"Xu","year":"2025","journal-title":"Front Endocrinol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1843595\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:47:06Z","timestamp":1781671626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1843595\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":36,"alternative-id":["10.3389\/fendo.2026.1843595"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1843595","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"article-number":"1843595"}}